Lu Huang1, Liu Yang2,3, Jie Huang3, Hong-Yi Tan3, Shi-Kun Liu1, Cheng-Xian Guo3, Xiao-Cong Zuo1, Guo-Ping Yang4,5, Qi Pei6,7. 1. Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, People's Republic of China. 2. Reproductive and Genetic Hospital of Citic-Xiangya, Changsha, Hunan, 410013, People's Republic of China. 3. Department of Pharmacy and Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Hunan, 410013, People's Republic of China. 4. Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, People's Republic of China. ygp9880@126.com. 5. Department of Pharmacy and Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Hunan, 410013, People's Republic of China. ygp9880@126.com. 6. Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, People's Republic of China. peiqi1028@126.com. 7. Department of Pharmacy and Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Hunan, 410013, People's Republic of China. peiqi1028@126.com.
Abstract
BACKGROUND AND OBJECTIVE: Telmisartan is an angiotensin receptor blocker used for the treatment of hypertension. The effects of gender and uridine diphosphate-glycosytransferase 1A1 (UGT1A1) genetic polymorphisms (rs4124874, rs4148323, and rs6742078) on telmisartan plasma concentration and blood pressure in Chinese patients with hypertension have been reported previously. In this study, we aimed to develop a population pharmacokinetic (PopPK) model to quantify the effects of gender and UGT1A1 polymorphisms on the pharmacokinetics of telmisartan. METHODS: Population pharmacokinetic analyses were performed using data collected prospectively from 58 Chinese patients with mild to moderate essential hypertension (aged 45-72 years; 36 men, 22 women) receiving 80 mg/day telmisartan orally for 4 weeks. Blood samples were collected in heparinized tubes at 0, 0.5, 1, and 6 h on day 28 after telmisartan administration. The plasma concentrations and UGT1A1 genetic variants were determined by high-performance liquid chromatography-mass spectrometry and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, respectively. RESULTS: A two-compartment pharmacokinetic structural model with first-order elimination and absorption best described the pharmacokinetic characteristics of telmisartan. Gender and triglyceride influenced the apparent oral clearance (CL) of telmisartan. UGT1A1 (rs4124874) affected the bioavailability (F1) of telmisartan. Lower CL and bioavailability resulted in higher plasma concentrations being observed in female subjects with UGT1A1 CC or CA genotype and high triglyceride. CONCLUSION: A PopPK model of telmisartan was established to confirm that UGT1A1 genotype, gender and triglyceride can affect the pharmacokinetics of telmisartan in Chinese patients with hypertension. Our findings can provide relevant pharmacokinetic parameters for further study of telmisartan.
BACKGROUND AND OBJECTIVE:Telmisartan is an angiotensin receptor blocker used for the treatment of hypertension. The effects of gender and uridine diphosphate-glycosytransferase 1A1 (UGT1A1) genetic polymorphisms (rs4124874, rs4148323, and rs6742078) on telmisartan plasma concentration and blood pressure in Chinese patients with hypertension have been reported previously. In this study, we aimed to develop a population pharmacokinetic (PopPK) model to quantify the effects of gender and UGT1A1 polymorphisms on the pharmacokinetics of telmisartan. METHODS: Population pharmacokinetic analyses were performed using data collected prospectively from 58 Chinese patients with mild to moderate essential hypertension (aged 45-72 years; 36 men, 22 women) receiving 80 mg/day telmisartan orally for 4 weeks. Blood samples were collected in heparinized tubes at 0, 0.5, 1, and 6 h on day 28 after telmisartan administration. The plasma concentrations and UGT1A1 genetic variants were determined by high-performance liquid chromatography-mass spectrometry and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, respectively. RESULTS: A two-compartment pharmacokinetic structural model with first-order elimination and absorption best described the pharmacokinetic characteristics of telmisartan. Gender and triglyceride influenced the apparent oral clearance (CL) of telmisartan. UGT1A1 (rs4124874) affected the bioavailability (F1) of telmisartan. Lower CL and bioavailability resulted in higher plasma concentrations being observed in female subjects with UGT1A1 CC or CA genotype and high triglyceride. CONCLUSION: A PopPK model of telmisartan was established to confirm that UGT1A1 genotype, gender and triglyceride can affect the pharmacokinetics of telmisartan in Chinese patients with hypertension. Our findings can provide relevant pharmacokinetic parameters for further study of telmisartan.
Authors: Xin Guo; Xiao-Ping Chen; Ze-Neng Cheng; Xi Luo; Ren Guo; Lei Chen; Jie Chen; Bo Chen; Jun Peng; Yuan-Jian Li Journal: Clin Chem Lab Med Date: 2009 Impact factor: 3.694
Authors: Mi Hye Kwon; Ji Na Yoon; Yu Jin Baek; Yu Chul Kim; Yong Yeon Cho; Hee Eun Kang Journal: Biopharm Drug Dispos Date: 2016-09 Impact factor: 1.627
Authors: Sylvia Deppe; Anne Ripperger; Johanna Weiss; Süleyman Ergün; Ralf A Benndorf Journal: Biochem Biophys Res Commun Date: 2014-01-03 Impact factor: 3.575
Authors: S Riedmaier; K Klein; U Hofmann; J E Keskitalo; P J Neuvonen; M Schwab; M Niemi; U M Zanger Journal: Clin Pharmacol Ther Date: 2009-09-30 Impact factor: 6.875